Table 2. Baseline and Outcome Characteristics by Study Phase.
| Characteristic | No. | ||
|---|---|---|---|
| Preintervention phase | Action phase | Continuous improvement phase | |
| Colorectal cancer | |||
| Facilities | 11 | 11 | 8 |
| Facility-months | 144 | 66 | 76 |
| Total tests | 20 373 | 10 062 | 9592 |
| Abnormal test results | 2718 | 1187 | 1225 |
| Trigger-positive test results | 650 | 307 | 329 |
| Patients with tests | 18 461 | 9385 | 9399 |
| Patients with abnormal test results | 2610 | 1156 | 1201 |
| Patients with trigger-positive test results | 634 | 300 | 328 |
| Site follow-up rate, mean % (percentage-point SD) | 76.0 (19.3) | 75.4 (15.5) | 76.2 (20.0) |
| Difference vs preintervention, mean (95% CI), percentage points | NA | −0.78 (−6.88 to 5.31)a | −0.02 (−8.59 to 8.55)b |
| P value | NA | .80 | >.99 |
| Lung cancer | |||
| Facilities | 10 | 10 | 8 |
| Facility-months | 124 | 60 | 76 |
| Total tests | 170 596 | 89 866 | 116 303 |
| Abnormal test results | 2888 | 1553 | 2873 |
| Trigger-positive test results | 876 | 517 | 1043 |
| Patients with tests | 113 032 | 60 781 | 83 399 |
| Patients with abnormal test results | 2801 | 1518 | 2763 |
| Patients with trigger-positive test results | 876 | 517 | 1043 |
| Site follow-up rate, mean % (percentage-point SD), | 72 (14.4) | 69.2 (13.0) | 67 (15.0) |
| Difference vs preintervention, mean (95% CI), percentage points | NA | 0.36 (−5.19 to 5.90)a | 0.89 (−6.85 to 8.63)b |
| P value | NA | .90 | .82 |
Abbreviation: NA, not applicable.
a
Primary outcome.
b
Secondary outcome.